The medical technology developer received series D funding from investors including existing backer Tencent, pushing its total funding past $120m.
China-based gene-sequencing technology developer Vision Medicals has raised RMB300m ($47m) in a series D round featuring internet and gaming group Tencent, DealStreetAsia reported today, citing a company statement.
Private equity firm Boyu Capital also participated in the round, as did CDH Venture and Growth Capital, a vehicle for alternative asset management firm CDH.
Founded in 2018, Vision Medicals is using gene editing technology to create diagnostics tools and therapeutics to treat infectious diseases.
The series D funds will be used…
Fernando Moncada Rivera
Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
